Michael Wang
Pediatric Hematology-Oncology · Aurora, CONPI 1588749238
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by CSL Behring at 26.9% of the total. Reporting peaked in 2019 at $74,151 and has fallen 50.6% since, to $36,658 in 2024. Among pediatric hematology-oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1247.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$60K
- Biomarin Pharmaceutical Inc.$36K
- Novo Nordisk$27K
- Bioverativ Therapeutics Inc.$24K
- Sanofi$22K
- HEMA Biologics, LLC$21K
- plus $33K from 7 others
Across 462 payments — averaging $5720.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$858K
- CSL Behring$516K
- Biomarin Pharmaceutical Inc.$365K
- Takeda Pharmaceuticals U.S.A., Inc.$237K
- Genentech, Inc.$159K
- Bioverativ Therapeutics Inc.$123K
- plus $384K from 9 others
What the payments were for
- Consulting fees$132,61859%
- Speaking & faculty fees$56,01125%
- Travel & lodging$30,58514%
- Food & beverage$5,3552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 38 | $60,372 |
| Biomarin Pharmaceutical Inc. | 22 | $36,442 |
| Novo Nordisk | 17 | $27,329 |
| Bioverativ Therapeutics Inc. | 23 | $23,747 |
| Sanofi | 14 | $22,116 |
| HEMA Biologics, LLC | 34 | $21,299 |
| Genentech USA, Inc. | 19 | $17,031 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $9,675 |
| F. Hoffmann-la Roche AG | 3 | $6,047 |
| Pfizer | 1 | $330 |
| Shire North American Group Inc | 2 | $94 |
| Bayer | 1 | $55 |
| Bristol Myers Squibb | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$224,570 in reported general payments places this provider in the 95th percentile of 60 pediatric hematology-oncology providers in Colorado.
See all pediatric hematology-oncology providers in Colorado →
Other pediatric hematology-oncology in Aurora
- Lia GoreAurora$68K
- Marilyn Manco JohnsonAurora$67K
- Michael VernerisAurora$60K
- Christopher McKinneyAurora$32K
- Daniel AmbrusoAurora$30K
- Taizo NakanoAurora$24K
- Hesham EissaAurora$23K
- Rachelle NussAurora$23K
- Terry FryAurora$20K
- Christopher NgAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.